EP1011608A4 - Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments - Google Patents
Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicamentsInfo
- Publication number
- EP1011608A4 EP1011608A4 EP99930160A EP99930160A EP1011608A4 EP 1011608 A4 EP1011608 A4 EP 1011608A4 EP 99930160 A EP99930160 A EP 99930160A EP 99930160 A EP99930160 A EP 99930160A EP 1011608 A4 EP1011608 A4 EP 1011608A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- ards
- cardiopulmonary
- ischemia
- administration
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8850198P | 1998-06-08 | 1998-06-08 | |
US88501P | 1998-06-08 | ||
US8865798P | 1998-06-09 | 1998-06-09 | |
US88657P | 1998-06-09 | ||
US93972 | 1998-06-09 | ||
US09/093,972 US6825174B2 (en) | 1995-06-07 | 1998-06-09 | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
PCT/US1999/012775 WO1999063938A2 (fr) | 1998-06-08 | 1999-06-08 | Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1011608A2 EP1011608A2 (fr) | 2000-06-28 |
EP1011608A4 true EP1011608A4 (fr) | 2002-05-15 |
Family
ID=27375993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99930160A Withdrawn EP1011608A4 (fr) | 1998-06-08 | 1999-06-08 | Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1011608A4 (fr) |
AU (1) | AU4675699A (fr) |
CA (1) | CA2316994A1 (fr) |
WO (1) | WO1999063938A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
US6214807B1 (en) | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
EP1255550A2 (fr) | 2000-02-17 | 2002-11-13 | Cv Therapeutics, Inc. | Procede d'identification et d'utilisation d'antagonistes du recepteur d'adenosine a2b pour agir sur la proliferation cellulaire d'un mammifere |
WO2001062979A2 (fr) | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Procede permettant d'identifier des agonistes partiels du recepteur a¿2a? |
US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
NZ556354A (en) | 2001-10-01 | 2008-10-31 | Univ Virginia | 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof |
CA2492855C (fr) | 2002-07-29 | 2012-09-18 | Cv Therapeutics, Inc. | Imagerie de perfusion myocardique au moyen d'agonistes de recepteur a2a |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
EP1778712B1 (fr) | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a2a |
US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
WO2006023272A1 (fr) | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | Analogues de 2-polycyclique propynyle adenosine presentant une activite agoniste de a2a |
EP1802317A2 (fr) | 2004-10-20 | 2007-07-04 | Cv Therapeutics, Inc. | Utilisation d'agonistes du recepteur de l'adenosine a2a |
AU2007212542B2 (en) | 2006-02-03 | 2013-01-31 | Gilead Sciences, Inc. | Process for preparing an A2A-Adenosine receptor agonist and its polymorphs |
EP2068850A1 (fr) * | 2006-06-22 | 2009-06-17 | Cv Therapeutics, Inc. | Utilisation d'agonistes de récepteur d'adénosine a<sb>2a</sb>dans le traitement d'une ischémie |
US8202848B2 (en) | 2008-03-17 | 2012-06-19 | Board Of Regents, The University Of Texas System | Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040162A1 (fr) * | 1995-06-07 | 1996-12-19 | East Carolina University | Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US6040296A (en) * | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
-
1999
- 1999-06-08 EP EP99930160A patent/EP1011608A4/fr not_active Withdrawn
- 1999-06-08 AU AU46756/99A patent/AU4675699A/en not_active Abandoned
- 1999-06-08 CA CA002316994A patent/CA2316994A1/fr not_active Abandoned
- 1999-06-08 WO PCT/US1999/012775 patent/WO1999063938A2/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040162A1 (fr) * | 1995-06-07 | 1996-12-19 | East Carolina University | Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens |
Non-Patent Citations (3)
Title |
---|
NYCE J W ET AL: "DNA ANTISENSE THERAPY FOR ASTHMA IN AN ANIMAL MODEL", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 385, 20 February 1997 (1997-02-20), pages 727 - 725, XP000891493, ISSN: 0028-0836 * |
NYCE J W: "Insight into adenosine receptor function using antisense and gene-knockout approaches", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 2, February 1999 (1999-02-01), pages 79 - 83, XP004157301, ISSN: 0165-6147 * |
See also references of WO9963938A3 * |
Also Published As
Publication number | Publication date |
---|---|
EP1011608A2 (fr) | 2000-06-28 |
WO1999063938A3 (fr) | 2000-01-27 |
WO1999063938A2 (fr) | 1999-12-16 |
AU4675699A (en) | 1999-12-30 |
CA2316994A1 (fr) | 1999-12-16 |
WO1999063938A9 (fr) | 2000-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1011608A4 (fr) | Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments | |
AU2001253167A1 (en) | System and methods for group retirement plan administration | |
ITRM910922A0 (it) | Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e metodo per applicarla. | |
AU3494695A (en) | System for electrolyzing fluids for in vivo administration to humans and other warm blooded mammals | |
AU1632601A (en) | System and method for pharmacy administration | |
BR9607862A (pt) | Composição farmacêutica filmogênica para administração transdérmica | |
DK1181027T3 (da) | Diætetisk eller farmaceutisk præparat til anvendelse til forebyggelsen eller behandling af hyperoxaluri | |
HUP0003121A3 (en) | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance | |
NO20013566D0 (no) | Farmasöytisk preparat med regulert frigjöringsvirkning | |
AU3136897A (en) | Compositions, methods and devices for the transdermal delivery of drugs | |
HUP9901779A3 (en) | Modified release multiple-units dosage composition | |
ZA981132B (en) | Methods, compositions and articles for reducing or preventing the effects of inflammation. | |
CA2253593A1 (fr) | Prevention et traitement du cancer colorectal par l'acide 6-fluoro-ursodesoxycholique (6-fudca) | |
ZA99104B (en) | Method for administering ASPB28-human insulin. | |
HK1036928A1 (en) | Safe needle, placebo needle, and needle set for double blind | |
IL183972A0 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
AU2001284413A1 (en) | Medicinal compositions for preventing or treating heart failure | |
IS4907A (is) | Nýjar bensímídasólafleiður sem vinna gegn magasári, aðferðir til að útbúa þær og lyfjablöndur sem innihalda þær | |
EP1013269A4 (fr) | Perfectionnement d'un systeme d'administration de medicament | |
AU6605100A (en) | Method and pharmaceutical composition for parenteral administration of iron | |
ZA976619B (en) | Benzimidazole derivatives, their preparation and their therapeutic applications. | |
NO20012518D0 (no) | Fremgangsmåte ved fremstilling av legemidler i fast administrasjonsform | |
AP2003002874A0 (en) | Echinocandin derivatives, preparation method and application as anti-fungal agents. | |
IS4198A (is) | Meðferð vegna aukaverkana sem tengjast gjöf á utanfrumublóðrauða | |
WO2001040241A3 (fr) | Derives de ketolide substitues par 6-o-alkyl-2-nor-2- |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000330 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 48/00 A, 7C 07H 21/04 B, 7C 07H 21/00 B, 7C 12N 5/00 B, 7C 12N 15/63 B, 7C 12N 15/79 B, 7C 12N 15/09 B |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 48/00 A, 7C 07H 21/00 B, 7C 07H 21/04 B, 7C 12N 5/00 B, 7C 12N 15/63 B, 7C 12N 15/79 B, 7C 12N 15/09 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020328 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050401 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1027510 Country of ref document: HK |